Irregular gastrointestinal drug absorption in Parkinson's disease

Bibliography

• von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005;15:473-90
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol 1993;60:609-12
   PubMedGoogle Scholar
• Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72
   PubMed Web of Science ®Google Scholar
• Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006;21:2042-51
   PubMed Web of Science ®Google Scholar
• Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007;22:1581-6
   PubMed Web of Science ®Google Scholar
• Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986;27:886-92
   PubMed Web of Science ®Google Scholar
• Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006;45:109-36
   PubMed Web of Science ®Google Scholar
• Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-30
   PubMed Web of Science ®Google Scholar
• Clissold BG, McColl CD, Reardon KR, Shiff M, Kempster PA. Longitudinal study of the motor response to levodopa in Parkinson's disease. Mov Disord 2006;21:2116-21
   PubMed Web of Science ®Google Scholar
• McColl CD, Reardon KA, Shiff M, Kempster PA. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord 2002;17:1227-34
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The “on-off” phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8
   PubMed Web of Science ®Google Scholar
• Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernas H, Karlen A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 1998;41:4939-49
   PubMed Web of Science ®Google Scholar
• Andersson I, Granerus AK, Jagenburg R, Svanborg A. Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake. Acta Med Scand 1975;198:415-20
   PubMed Web of Science ®Google Scholar
• Kim HR, Park SW, Cho HJ, et al. Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharmacol Res 2007;56:224-36
   PubMed Web of Science ®Google Scholar
• Gundert-Remy U, Hildebrandt R, Stiehl A, Weber E, Zurcher G, Da Prada M. Intestinal absorption of levodopa in man. Eur J Clin Pharmacol 1983;25:69-72
   PubMed Web of Science ®Google Scholar
• Rivera-Calimlim L, Dujovne CA, Morgan JP, Lasagna L, Bianchine JR. Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest 1971;1:313-20
   PubMed Web of Science ®Google Scholar
• Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RS. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986;20:258-62
   PubMed Web of Science ®Google Scholar
• Lennernas H, Nilsson D, Aquilonius SM, Ahrenstedt O, Knutson L, Paalzow LK. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol 1993;35:243-50
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients. Eur J Clin Pharmacol 1998;54:303-8
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lennernas H, Gomes-Trolin C, Aquilonius SM. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 2002;25:89-96
   PubMed Web of Science ®Google Scholar
• Simon N, Gantcheva R, Bruguerolle B, Viallet F. The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease. Parkinsonism Rel Disord 2004;10:137-42
   PubMed Web of Science ®Google Scholar
• Chan PL, Nutt JG, Holford NH. Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. J Pharmacokinet Pharmacodyn 2005;32:307-31
   PubMed Web of Science ®Google Scholar
• Muhlack S, Woitalla D, Welnic J, Twiehaus S, Przuntek H, Muller T. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. Neurosci Lett 2004;363:284-7
   PubMed Web of Science ®Google Scholar
• Murata M, Mizusawa H, Yamanouchi H, Kanazawa I. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J Neural Transm 1996;103:1177-85
   PubMed Web of Science ®Google Scholar
• Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 2001;16:1041-7
   PubMed Web of Science ®Google Scholar
• Lennernas H. Human intestinal permeability. J Pharm Sci 1998;87:403-10
   PubMed Web of Science ®Google Scholar
• Nilsson D, Fagerholm U, Lennernas H. The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum. Pharm Res 1994;11:1540-7
   PubMed Web of Science ®Google Scholar
• Takamatsu N, Welage LS, Idkaidek NM, et al. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm Res 1997;14:1127-32
   PubMed Web of Science ®Google Scholar
• Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-15
   PubMed Web of Science ®Google Scholar
• Szurszewski JH. A migrating electric complex of canine small intestine. Am J Physiol 1969;217:1757-63
   PubMed Web of Science ®Google Scholar
• Code CF, Marlett JA. The interdigestive myo-electric complex of the stomach and small bowel of dogs. J Physiol 1975;246:289-309
   PubMed Web of Science ®Google Scholar
• Rees WD, Malagelada JR, Miller LJ, Go VL. Human interdigestive and postprandial gastrointestinal motor and gastrointestinal hormone patterns. Dig Dis Sci 1982;27:321-9
   PubMed Web of Science ®Google Scholar
• Kellow JE, Borody TJ, Phillips SF, Tucker RL, Haddad AC. Human interdigestive motility: variations in patterns from esophagus to colon. Gastroenterology 1986;91:386-95
   PubMed Web of Science ®Google Scholar
• Oberle RL, Chen TS, Lloyd C, et al. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 1990;99:1275-82
   PubMed Web of Science ®Google Scholar
• Hunt JN, MacDonald I. The influence of volume on gastric emptying. J Physiol 1954;126:459-74
   PubMed Web of Science ®Google Scholar
• Hunt JN, Spurrell WR. The pattern of emptying of the human stomach. J Physiol 1951;113:157-68
   PubMed Web of Science ®Google Scholar
• Kellly KA. Motlity of the stomach and gastroduodenal junction. In: Physiology of the Gastrointestinal Tract. Johnson LR, editor. New York: Raven Press; 1981. p. 1073-95
   Google Scholar
• Mojaverian P, Reynolds JC, Ouyang A, Wirth F, Kellner PE, Vlasses PH. Mechanism of gastric emptying of a nondisintegrating radiotelemetry capsule in man. Pharm Res 1991;8:97-100
   PubMed Web of Science ®Google Scholar
• Burn-Murdoch R, Fisher MA, Hunt JN. Does lying on the right side increase the rate of gastric emptying? J Physiol 1980;302:395-8
   PubMed Web of Science ®Google Scholar
• Bennett CE, Hardy JG, Wilson CG. The influence of posture on the gastric emptying of antacids. Int J Pharm 1984;21:341-7
   Web of Science ®Google Scholar
• Brogna A, Ferrara R, Bucceri AM, Lanteri E, Catalano F. Influence of aging on gastrointestinal transit time. An ultrasonographic and radiologic study. Invest Radiol 1999;34:357-9
   PubMed Web of Science ®Google Scholar
• Madsen JL, Graff J. Effects of ageing on gastrointestinal motor function. Age Ageing 2004;33:154-9
   PubMed Web of Science ®Google Scholar
• Graff J, Brinch K, Madsen JL. Gastrointestinal mean transit times in young and middle-aged healthy subjects. Clin Physiol 2001;21:253-9
   PubMedGoogle Scholar
• Minami H, McCallum RW. The physiology and pathophysiology of gastric emptying in humans. Gastroenterology 1984;86:1592-610
   PubMed Web of Science ®Google Scholar
• Bogentoft C, Carlsson I, Ekenved G, Magnusson A. Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms. Eur J Clin Pharmacol 1978;14:351-5
   PubMed Web of Science ®Google Scholar
• Smith HJ, Feldman M. Influence of food and marker length on gastric emptying of indigestible radiopaque markers in healthy humans. Gastroenterology 1986;91:1452-5
   PubMed Web of Science ®Google Scholar
• Russell J, Bass P. Canine gastric emptying of polycarbophil: an indigestible, particulate substance. Gastroenterology 1985;89:307-12
   PubMed Web of Science ®Google Scholar
• Meyer JH, Elashoff J, Porter-Fink V, Dressman J, Amidon GL. Human postprandial gastric emptying of 1 – 3-millimeter spheres. Gastroenterology 1988;94:1315-25
   PubMed Web of Science ®Google Scholar
• Meyer JH, Dressman J, Fink A, Amidon G. Effect of size and density on canine gastric emptying of nondigestible solids. Gastroenterology 1985;89:805-13
   PubMed Web of Science ®Google Scholar
• Meyer JH, Thomson JB, Cohen MB, Shadchehr A, Mandiola SA. Sieving of solid food by the canine stomach and sieving after gastric surgery. Gastroenterology 1979;76:804-13
   PubMed Web of Science ®Google Scholar
• Mayer EA, Thomson JB, Jehn D, et al. Gastric emptying and sieving of solid food and pancreatic and biliary secretions after solid meals in patients with nonresective ulcer surgery. Gastroenterology 1984;87:1264-71
   PubMed Web of Science ®Google Scholar
• Hinder RA, Kelly KA. Canine gastric emptying of solids and liquids. Am J Physiol 1977;233:E335-40
   PubMed Web of Science ®Google Scholar
• Feldman M, Smith HJ, Simon TR. Gastric emptying of solid radiopaque markers: studies in healthy subjects and diabetic patients. Gastroenterology 1984;87:895-902
   PubMed Web of Science ®Google Scholar
• Coupe AJ, Davis SS, Evans DF, Wilding IR. Correlation of the gastric emptying of nondisintegrating tablets with gastrointestinal motility. Pharm Res 1991;8:1281-5
   PubMed Web of Science ®Google Scholar
• Khosla R, Davis SS. The effect of tablet size on the gastric emptying of non-disintegrating tablets. Int J Pharm 1990;62:R9-11
   Web of Science ®Google Scholar
• Kerlin P, Zinsmeister A, Phillips S. Relationship of motility to flow of contents in the human small intestine. Gastroenterology 1982;82:701-6
   PubMed Web of Science ®Google Scholar
• Kerlin P, Phillips S. Variability of motility of the ileum and jejunum in healthy humans. Gastroenterology 1982;82:694-700
   PubMed Web of Science ®Google Scholar
• Mojaverian P, Chan K, Desai A, John V. Gastrointestinal transit of a solid indigestible capsule as measured by radiotelemetry and dual gamma scintigraphy. Pharm Res 1989;6:719-24
   PubMed Web of Science ®Google Scholar
• Khosla R, Feely LC, Davis SS. Gastrointestinal transit of non-disintegrating tablets in fed subjects. Int J Pharm 1989;53:107-17
   Web of Science ®Google Scholar
• Davis SS, Hardy JG, Taylor MJ, Whalley DR, Wilson CG. A comparative study of the gastrointestinal transit of a pellet and tablet formulation. Int J Pharm 1984;21:167-77
   Web of Science ®Google Scholar
• Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 1991;8:360-4
   PubMed Web of Science ®Google Scholar
• Christensen FN, Davis SS, Hardy JG, Taylor MJ, Whalley DR, Wilson CG. The use of gamma scintigraphy to follow the gastrointestinal transit of pharmaceutical formulations. J Pharm Pharmacol 1985;37:91-5
   PubMed Web of Science ®Google Scholar
• Birkebaek NH, Memmert K, Mortensen J, Dirksen H, Christensen MF. Fractional gastrointestinal transit time: intra- and interindividual variation. Nucl Med Commun 1990;11:247-52
   PubMed Web of Science ®Google Scholar
• Narducci F, Bassotti G, Gaburri M, Morelli A. Twenty four hour manometric recording of colonic motor activity in healthy man. Gut 1987;28:17-25
   PubMed Web of Science ®Google Scholar
• Singaram C, Ashraf W, Gaumnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995;346:861-4
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003;2:107-16
   PubMed Web of Science ®Google Scholar
• Edwards L, Quigley EM, Hofman R, Pfeiffer RF. Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study. Mov Disord 1993;8:83-6
   PubMed Web of Science ®Google Scholar
• Krygowska-Wajs A, Lorens K, Thor P, Szczudlik A, Konturek S. Gastric electromechanical dysfunction in Parkinson's disease. Funct Neurol 2000;15:41-6
   PubMed Web of Science ®Google Scholar
• Goetze O, Wieczorek J, Mueller T, Przuntek H, Schmidt WE, Woitalla D. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci Lett 2005;375:170-3
   PubMed Web of Science ®Google Scholar
• Davies KN, King D, Billington D, Barrett JA. Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease. Postgrad Med J 1996;72:164-7
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996;46:1051-4
   PubMed Web of Science ®Google Scholar
• Naftali T, Gadoth N, Huberman M, Novis B. Electrogastrography in patients with Parkinson's disease. Can J Neurol Sci 2005;32:82-6
   PubMed Web of Science ®Google Scholar
• Goetze O, Nikodem AB, Wiezcorek J, et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil 2006;18:369-75
   PubMed Web of Science ®Google Scholar
• Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility. Neurology 1988;38:419-21
   PubMed Web of Science ®Google Scholar
• Melamed E, Bitton V, Zelig O. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology 1986;36:100-3
   PubMedGoogle Scholar
• Oh JD, Chase TN. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids 2002;23:133-9
   PubMed Web of Science ®Google Scholar
• Sanchez LD, Corwell B, Berkoff D. Medical problems of marathon runners. Am J Emerg Med 2006;24:608-15
   PubMed Web of Science ®Google Scholar
• Reuter I, Harder S, Engelhardt M, Baas H. The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2000;15:862-8
   PubMed Web of Science ®Google Scholar
• Muhlack S, Welnic J, Woitalla D, Muller T. Exercise improves efficacy of levodopa in patients with Parkinson's disease. Mov Disord 2007;22:427-30
   PubMed Web of Science ®Google Scholar
• Friedenberg FK, Parkman HP. Delayed gastric emptying: whom to test, how to test, and what to do. Curr Treat Options Gastroenterol 2006;9:295-304
   PubMedGoogle Scholar
• Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004;19:379-90
   PubMed Web of Science ®Google Scholar
• Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007;22:304-10
   PubMed Web of Science ®Google Scholar
• Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol Motil 2005;17:643-53
   PubMed Web of Science ®Google Scholar
• Karamanolis G, Tack J. Promotility medications – now and in the future. Dig Dis 2006;24:297-307
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Koren M, Ziv I, Achiron A, Melamed E. Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995;10:81-4
   PubMed Web of Science ®Google Scholar
• Neira WD, Sanchez V, Mena MA, de Yebenes JG. The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease. Mov Disord 1995;10:66-70
   PubMed Web of Science ®Google Scholar
• Jost WH, Schimrigk K. Long-term results with cisapride in Parkinson's disease. Mov Disord 1997;12:423-5
   PubMed Web of Science ®Google Scholar
• Jost WH. Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management. Drugs Aging 1997;10:249-58
   PubMed Web of Science ®Google Scholar
• Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 1999;33:429-40
   PubMed Web of Science ®Google Scholar
• Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997;12:952-7
   PubMed Web of Science ®Google Scholar
• Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M. Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. Arch Intern Med 1986;146:2070-1
   PubMed Web of Science ®Google Scholar
• Asai H, Udaka F, Hirano M, et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease. Parkinsonism Relat Disord 2005;11:499-502
   PubMed Web of Science ®Google Scholar
• Deleu D, Jacob P, Chand P, Sarre S, Colwell A. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology 2006;67:897-9
   PubMed Web of Science ®Google Scholar
• Hauser RA, Schwarzschild MA. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging 2005;22:471-82
   PubMed Web of Science ®Google Scholar
• Muller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 2006;29:61-7
   PubMed Web of Science ®Google Scholar
• Malcolm SL, Allen JG, Bird H, et al. Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers. Eur Neurol 1987;27(Suppl 1):28-35
   PubMedGoogle Scholar
• Pfeiffer RF. Antiparkinsonian agents. Drug interactions of clinical significance. Drug Saf 1996;14:343-54
   PubMed Web of Science ®Google Scholar
• Robertson DR, Renwick AG, Wood ND, et al. The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol 1990;29:47-53
   PubMed Web of Science ®Google Scholar
• Karstaedt PJ, Pincus JH. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol 1992;49:149-51
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Martinelli P, Procaccianti G, Albani F, Baruzzi A. Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease. Effect on levodopa bioavailability. Clin Neuropharmacol 1991;14:148-55
   PubMed Web of Science ®Google Scholar
• Campbell NR, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. Clin Pharmacol Ther 1989;45:220-5
   PubMed Web of Science ®Google Scholar
• Durso R, Evans JE, Josephs E, et al. Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol 2000;40:854-60
   PubMed Web of Science ®Google Scholar
• Kurth MC. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide. Drugs Aging 1997;10:332-40
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Clin Neuropharmacol 1999;22:351-5
   PubMed Web of Science ®Google Scholar
• Metman LV, Hoff J, Mouradian MM, Chase TN. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 1994;9:463-5
   PubMed Web of Science ®Google Scholar
• Nagayama H, Hamamoto M, Ueda M, Nito C, Yamaguchi H, Katayama Y. The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol 2004;27:270-3
   PubMed Web of Science ®Google Scholar
• Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations. Neurology 2006;66:1824-9
   PubMed Web of Science ®Google Scholar
• Descombes S, Bonnet AM, Gasser UE, et al. Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease. Neurology 2001;56:1239-42
   PubMed Web of Science ®Google Scholar
• Goole J, Deleuze P, Vanderbist F, Amighi K. New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer. Eur J Pharm Biopharm; 2008:68(2):310-8
   PubMed Web of Science ®Google Scholar
• Klausner EA, Lavy E, Barta M, Cserepes E, Friedman M, Hoffman A. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm Res 2003;20:1466-73
   PubMed Web of Science ®Google Scholar
• Bredenberg S, Nyholm D, Aquilonius SM, Nystrom C. An automatic dose dispenser for microtablets – a new concept for individual dosage of drugs in tablet form. Int J Pharm 2003;261:137-46
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Inzelberg R, Giladi N, et al. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord 2002;17:297-302
   PubMed Web of Science ®Google Scholar
• Blindauer K, Shoulson I, Oakes D, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol 2006;63:210-6
   PubMed Web of Science ®Google Scholar
• Johnston TH, Fox SH, Brotchie JM. Advances in the delivery of treatments for Parkinson's disease. Expert Opin Drug Deliv 2005;2:1059-73
   PubMedGoogle Scholar
• Menon R, Stacy M. Apomorphine in the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:1941-50
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol 1996;39:400-4
   PubMed Web of Science ®Google Scholar
• Muller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov Disord 2006;21:332-6
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-9
   PubMed Web of Science ®Google Scholar
• Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother 2006;6:1403-11
   PubMedGoogle Scholar
• Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004;21:687-709
   PubMed Web of Science ®Google Scholar
• Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002;125:2058-66
   PubMed Web of Science ®Google Scholar
• Naidu Y, Chaudhuri KR. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease. Expert Opin Drug Deliv 2007;4:111-8
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 2007;68:1262-7
   PubMed Web of Science ®Google Scholar
• Koziorowski D, Friedman A. Levodopa “drug holiday” with amantadine infusions as a treatment of complications in Parkinson's disease. Mov Disord 2007;22:1033-6
   PubMed Web of Science ®Google Scholar
• Schapira AH, Bezard E, Brotchie J, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 2006;5:845-54
   PubMed Web of Science ®Google Scholar
• Wolters E. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl):S18-23
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007;22:1901-11
   PubMed Web of Science ®Google Scholar
• Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-63
   PubMed Web of Science ®Google Scholar